Healthcare proved to be a resilient market for mergers and acquisitions in 2024, despite deal volume declining 9% from 2023. ...

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the stock.

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

A large pharmaceutical company collaborated with DelveInsight to evaluate CDMO companies for API and FD development. DelveInsight provided a comprehensive one-time report benchmarking top contract ...

Copenhagen Airport in 2024, 3.1 million more than the previous year.December was the best December ever at Copenhagen Airport. 2.2 million passengers traveled through Denmark’s international airport ...